Protective efficacy of a hydroxy fatty acid against gastric Helicobacter infections

Helicobacter

Volumn 22, Issue 6, 2017, Pages

  Matsui, Hidenori ^a   Takahashi, Tetsufumi ^b   Murayama, Somay Y ^c   Kawaguchi, Marina ^d   Matsuo, Koichi ^e   Nakamura, Masahiko ^a  

^a KITASATO UNIVERSITY   (Japan)

^b YOKOHAMA COLLEGE OF PHARMACY   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d Nitto Pharmaceutical Industries   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

alternative menaquinone biosynthesis; Helicobacter suis; hydroxy fatty acid; mucosa associated lymphoid tissue lymphoma

Indexed keywords

10 HYDROXY 12 OCTADECENOIC ACID; 10 HYDROXYOCTADECANOIC ACID; 10 OXO 12 OCTADECENOIC ACID; 10 OXO TRANS 11 OCTADECENOIC ACID; CD19 ANTIGEN; CD20 ANTIGEN; DOCOSAHEXAENOIC ACID; HYDROXY FATTY ACID; ICOSAPENTAENOIC ACID; KI 67 ANTIGEN; LINOLEIC ACID; MENATETRENONE; OLEIC ACID; STEARIC ACID DERIVATIVE; UNCLASSIFIED DRUG; 10-HYDROXYSTEARIC ACID; FARNOQUINONE; OMEGA 6 FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL LOAD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HELICOBACTER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HELICOBACTER SUIS; LYMPH FOLLICLE; MARGINAL ZONE LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH MUCUS; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; HELICOBACTER HEILMANNII; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ANIMALS; BACTERIAL LOAD; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; FATTY ACIDS, OMEGA-6; FEMALE; HELICOBACTER HEILMANNII; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICE, INBRED C57BL; REAL-TIME POLYMERASE CHAIN REACTION; STEARIC ACIDS; TREATMENT OUTCOME; VITAMIN K 2;

EID: 85033226400     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12430     Document Type: Article

References (40)

1. Kurosu M, Begari E. Vitamin K2 in electron transport system: are enzymes involved in vitamin K2 biosynthesis promising drug targets? Molecules. 2010;15:1531-1553.
2. Bentley R, Meganathan R. Biosynthesis of vitamin K (menaquinone) in bacteria. Microbiol Rev. 1982;46:241-280.
3. Hiratsuka T, Furihata K, Ishikawa J, et al. An alternative menaquinone biosynthetic pathway operating in microorganisms. Science. 2008;321:1670-1673.
4. Dairi T. An alternative menaquinone biosynthetic pathway operating in microorganisms: an attractive target for drug discovery to pathogenic Helicobacter and Chlamydia strains. J Antibiot. 2009;62:347-352.
5. Zhi XY, Yao JC, Tang SK, Huang Y, Li HW, Li WJ. The futalosine pathway played an important role in menaquinone biosynthesis during early prokaryote evolution. Genome Biol Evol. 2014;6:149-160.
6. Arakawa C, Kuratsu M, Furihata K, et al. Diversity of the early step of the futalosine pathway. Antimicrob Agents Chemother. 2011;55:913-916.
7. Li X, Apel D, Gaynor EC, Tanner ME. 5’-methylthioadenosine nucleosidase is implicated in playing a key role in a modified futalosine pathway for menaquinone biosynthesis in Campylobacter jejuni. J Biol Chem. 2011;286:19392-1938.
8. Barta ML, Thomas K, Yuan H, et al. Structural and biochemical characterization of Chlamydia trachomatis hypothetical protein CT263 supports that menaquinone synthesis occurs through the futalosine pathway. J Biol Chem. 2014;289:32214-32229.
9. Yamamoto T, Matsui H, Yamaji K, et al. Narrow-spectrum inhibitors targeting an alternative menaquinone biosynthetic pathway of Helicobacter pylori. J Infect Chemother. 2016;22:587-592.
10. Jones PJH, Kubow S. Lipids, sterols, and their metabolites. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, eds. Modern Nutrition in Health and Disease, 10th edn. Baltimore, MD, USA: Lippincott Williams & Wilkins; 2006:92-122.
11. Patterson E, Wall R, Fitzgerald GF, Ross RP, Stanton C. Health implications of high dietary omega-6 polyunsaturated fatty acids. J Nutr Metab. 2012;2012:539426.
12. Park JM, Jeong M, Kim EH, Han YM, Kwon SH, Hahm KB. Omega-3 polyunsaturated fatty acids intake to regulate Helicobacter pylori-associated gastric diseases as nonantimicrobial dietary approach. Biomed Res Int. 2015;2015:712363.
13. Tanaka R, Kunisada T, Kushida N, et al. Branched fatty acids inhibit the biosynthesis of menaquinone in Helicobacter pylori. J Antibiot. 2011;64:151-153.
14. Ogawa J, Kishino S, Ando A, Sugimoto S, Mihara K, Shimizu S. Production of conjugated fatty acids by lactic acid bacteria. J Biosci Bioeng. 2005;100:355-364.
15. Lee A, O'Rourke J, De Ungria MC, Robertson B, Daskalopoulos G, Dixon MF. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology. 1997;112:1386-1397.
16. Matsui H, Aikawa C, Sekiya Y, Takahashi S, Murayama SY, Nakamura M. Evaluation of antibiotic therapy for eradication of “Candidatus Helicobacter heilmannii”. Antimicrob Agents Chemother. 2008;52:2988-2989.
17. Osaki T, Yamaguchi H, Taguchi H, et al. Establishment and characterisation of a monoclonal antibody to inhibit adhesion of Helicobacter pylori to gastric epithelial cells. J Med Microbiol. 1998;47:505-512.
18. Matsumoto T, Takahashi T, Yamada H. A novel approach for screening of new anti-Helicobacter pylori substances. Biol Pharm Bull. 2008;31:143-145.
19. Nakamura M, Murayama SY, Serizawa H, et al. “Candidatus Helicobacter heilmannii” from a cynomolgus monkey induces gastric mucosa-associated lymphoid tissue lymphoma in C57BL/6 mice. Infect Immun. 2007;75:1214-1222.
20. Matsui H, Takahashi T, Murayama SY, et al. Draft genome sequence of Helicobacter suis strain SNTW101, isolated from a Japanese patient with nodular gastritis. Genome Announc. 2016;4:e00934-16.
21. Matsui H, Takahashi T, Murayama SY, et al. Development of new PCR primers by comparative genomics for the detection of Helicobacter suis in gastric biopsy specimens. Helicobacter. 2014;19:260-271.
22. Matsui H, Takahashi T, Overby A, et al. Mouse models for assessing the protective efficacy of Lactobacillus gasseri SBT2055 against Helicobacter suis infection associated with the development of gastric mucosa-associated lymphoid tissue lymphoma. Helicobacter. 2015;20:291-298.
23. Chisholm SA, Owen RJ. Development and application of a novel screening PCR assay for direct detection of ‘Helicobacter heilmannii’-like organisms in human gastric biopsies in Southeast England. Diagn Microbiol Infect Dis. 2003;46:1-7.
24. Pahl A, Kuhlbrandt U, Brune K, Rollinghoff M, Gessner A. Quantitative detection of Borrelia burgdorferi by real-time PCR. J Clin Microbiol. 1999;37:1958-1963.
25. Wong ML, Medrano JF. Real-time PCR for mRNA quantitation. Biotechniques. 2005;39:75-85.
26. Matsui H, Nakatani Y, Yoshida H, et al. Flesh-eating Streptococcus pyogenes triggers the expression of receptor activator of nuclear factor-kappaB ligand. Cell Microbiol. 2016;18:1390-1404.
27. Sunanliganon C, Thong-Ngam D, Tumwasorn S, Klaikeaw N. Lactobacillus plantarum B7 inhibits Helicobacter pylori growth and attenuates gastric inflammation. World J Gastroenterol. 2012;18:2472-2480.
28. Kishino S, Takeuchi M, Park SB, et al. Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition. Proc Natl Acad Sci USA. 2013;110:17808-17813.
29. Miyamoto J, Mizukure T, Park SB, et al. A gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway. J Biol Chem. 2015;290:2902-2918.
30. Wang Y, Qian Y, Fang Q, et al. Saturated palmitic acid induces myocardial inflammatory injuries through direct binding to TLR4 accessory protein MD2. Nat Commun. 2017;8:13997.
31. Bergamino L, Capra V, Biancheri R, et al. Immunomodulatory therapy in recurrent acute necrotizing encephalopathy ANE1: is it useful? Brain Dev. 2012;34:384-391.
32. Øverby A, Murayama SY, Michimae H, et al. Prevalence of gastric non-Helicobacter pylori-helicobacters in Japanese patients with gastric disease. Digestion. 2017;95:61-66.
33. Nakamura M, Takahashi T, Matsui H, et al. New pharmaceutical treatment of gastric MALT lymphoma: anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib. Curr Pharm Des. 2014;20:1097-1103.
34. Nakamura M, Øverby A, Murayama SY, et al. Gastric non-Helicobacter pylori helicobacter: its significance in human gastric diseases. In: Suzuki H, Warren R, Marshall B, eds. Helicobacter pylori. Part II. Tokyo, Japan: Springer Japan; 2016:131-140.
35. Øverby A, Murayama SY, Matsui H, Nakamura M. In the aftermath of Helicobacter pylori: other Helicobacters rising up to become the next gastric epidemic? Digestion. 2016;93:260-265.
36. Baele M, Decostere A, Vandamme P, et al. Isolation and characterization of Helicobacter suis sp. nov. from pig stomachs. Int J Syst Evol Microbiol. 2008;58:1350-1358.
37. Pena JA, Li SY, Wilson PH, Thibodeau SA, Szary AJ, Versalovic J. Genotypic and phenotypic studies of murine intestinal lactobacilli: species differences in mice with and without colitis. Appl Environ Microbiol. 2004;70:558-568.
38. Blaecher C, Bauwens E, Tay A, et al. A novel isolation protocol and probe-based RT-PCR for diagnosis of gastric infections with the zoonotic pathogen Helicobacter suis. Helicobacter. 2017;22:e12369. https://doi.org/10.1111/hel.12369.
39. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology. 2002;40:2-11.
40. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51:364-369.